Drugs that contain Omacetaxine Mepesuccinate
1. Synribo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7842687 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
| USRE45128 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
| Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml); Treatment of patients with leukemia including chronic myeloid/myelogenous...
Dosage: POWDER;SUBCUTANEOUS
How can I launch a generic of SYNRIBO before it's drug patent expiration?
More Information on Dosage
SYNRIBO family patents
